Cantor Fitzgerald maintains Vertex stock at Overweight, $480 target
Cantor Fitzgerald reiterated its Overweight rating and a $480.00 price target for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), which currently trades at $438.40 with a market capitalization of ...
Business Insider26d
Vertex Pharmaceuticals (VRTX) Receives a Buy from Cantor Fitzgerald
Cantor Fitzgerald analyst Olivia Brayer maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report) yesterday and set a price target of $480.00. The company’s shares closed ...
Cantor Fitzgerald maintains Vertex stock Overweight rating
Cantor Fitzgerald reaffirmed its Overweight rating on Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) with a consistent price target of $480.00. According to InvestingPro data, Vertex, a prominent ...